Cor Vasa 2010, 52(7-8):441-446 | DOI: 10.33678/cor.2010.118

Ventricular arrhythmias and sudden death in hypertrophic cardiomyopathy

Václav Durdil
Kardiologické oddělení, Kardiovaskulární centrum, Fakultní nemocnice Motol, Praha, Česká republika

Hypertrophic cardiomyopathy (HCM) is the most frequent hereditary heart disease. Clinical features of the disease include ventricular arrhythmias. The pathogenesis of ventricular arrhythmias in HCM is multifactorial, with less severe forms of ventricular ectopy and non-sustained ventricular tachycardia being the most common finding. A proportion of patients is at increased risk of sudden death secondary to sustained ventricular arrhythmia or ventricular fibrillation. The mainstay of care of HCM patients is identification of these groups at risk and subsequent prevention of sudden death using the implantable cardioverter-defibrillator (ICD). Those with recurrent malignant forms of ventricular arrhythmias and frequent use of ICD are scheduled for antiarrhythmic therapy or catheter ablation.

Keywords: Hypertrophic cardiomyopathy; Ventricular arrhythmias; Sudden cardiac death; Implantable cardioverter-defibrillator; Catheter ablation

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Durdil V. Ventricular arrhythmias and sudden death in hypertrophic cardiomyopathy. Cor Vasa. 2010;52(7-8):441-446. doi: 10.33678/cor.2010.118.
Download citation

References

  1. http://genepath.med.harvard.edu/~seidman/cg3/index.html
  2. Veselka J, et al. Hypertrofická kardiomyopatie a příbuzná témata. Praha: Galén, 2006.
  3. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:697-704. Go to original source... Go to PubMed...
  4. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-1374. Go to original source... Go to PubMed...
  5. Savage DD, Seides SF, Maron BJ, et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979;59:866-875. Go to original source...
  6. Maron BJ, Semsarian C, Shen WK, et al. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm 2009;6:599-602. Go to original source... Go to PubMed...
  7. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-373. Go to original source... Go to PubMed...
  8. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596-1601. Go to original source...
  9. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998;31: 1081-1085. Go to original source...
  10. Táborský M, Kautzner J, Bytešník J, et al. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterů-defibrilátorů a systémů pro srdeční resynchronizační léčbu 2009. Cor Vasa 2009;51:602-618. Go to original source...
  11. European Heart Rhythm Association; Heart Rhythm Society; Zipes DP, Camm AJ, Borggrefe M, et al., American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247-e346.
  12. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-e62. Go to original source... Go to PubMed...
  13. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-416. Go to original source... Go to PubMed...
  14. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007;93:708-710. Go to original source... Go to PubMed...
  15. Fananapazir L, Chang AC, Epstein SE, et al. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992;86:730-740. Go to original source... Go to PubMed...
  16. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-1713. Go to original source...
  17. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002;87:169-176. Go to original source...
  18. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-538. Go to original source...
  19. Homolová S, Zemánek D, Veselka J. Stratifikace rizika náhlé smrti u hypertrofické kardiomyopatie. Cor Vasa 2009;51:38-40. Go to original source...
  20. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-412. Go to original source... Go to PubMed...
  21. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119:1703-1710. Go to original source... Go to PubMed...
  22. Elliott P, McKenna W. The science of uncertainty and the art of probability: syncope and its consequences in hypertrophic cardiomyopathy. Circulation 2009;119:1697-1699. Go to original source... Go to PubMed...
  23. Monserrat, L, Elliott, PM, Gimeno, JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-879. Go to original source...
  24. Gimeno JR, Tomé-Esteban M, Lofiego C, et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599-2605. Go to original source... Go to PubMed...
  25. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-1785. Go to original source... Go to PubMed...
  26. Olivotto I, Gistri R, Petrone P, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:315-321. Go to original source...
  27. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33: 2044-2051. Go to original source...
  28. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-1941. Go to original source... Go to PubMed...
  29. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303. Go to original source... Go to PubMed...
  30. Efthimiadis GK, Parcharidou DG, Giannakoulas G, et al. Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 2009;104:695-699. Go to original source... Go to PubMed...
  31. Cuoco FA, Spencer WH, Fernandes VL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;52:1718-1723. Go to original source... Go to PubMed...
  32. Noseworthy PA, Rosenberg MA, Fifer MA, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2009;104:128-132. Go to original source... Go to PubMed...
  33. McMahon CJ, Nagueh SF, Pignatelli RH, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004;109:1756-1762. Go to original source... Go to PubMed...
  34. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804. Go to original source...
  35. Yamada M, Elliott PM, Kaski JC, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur Heart J 1998;19:500-507. Go to original source... Go to PubMed...
  36. Maron BJ, Maron MS, Lesser JR, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008;101:544-547. Go to original source... Go to PubMed...
  37. Maron MS, Buros J, Gibson CM, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circulation 2008;1:184-191. Go to original source... Go to PubMed...
  38. Leonardi S, Raineri C, De Ferrari GM, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2003-2010. Go to original source... Go to PubMed...
  39. Boriani G, Rapezzi C, Biffi M, et al. Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2002;13:954. Go to original source... Go to PubMed...
  40. Stafford WJ, Trohman RG, Bilsker M, et al. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7:701-704. Go to original source...
  41. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104: 2517-2524. Go to original source...
  42. Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 2010;12:313-321. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.